Abstract: The present invention relates to a pharmaceutical composition comprising a population of cells including irradiated hematopoietic stem cells, and a method for producing the pharmaceutical composition, specifically, a pharmaceutical composition for treating an ischemic disease, comprising a population of cells including irradiated hematopoietic stem cells, wherein the irradiation is irradiation at 50 Gy or less, and a method for producing the pharmaceutical composition.

Abstract: An object of the present invention is to provide a therapeutic agent for arthrosis, which contains synovium-derived mesenchymal stem cells having a molecule essential for joint medical treatment, and a production method for the therapeutic agent for arthrosis. According to the present invention, there is provided a therapeutic agent for arthrosis, which contains synovium-derived mesenchymal stem cells having any one or more kinds of surface antigens of integrin ?1 or platelet-derived growth factor receptor ?.

Abstract: The present invention relates to a method of manufacturing an animal cartilage-derived injectable composition, an injectable composition manufactured by the method, and a use thereof. The injectable composition of the present invention includes a collagen-containing biomaterial in a formulation injectable into joint cavity and may induce cartilage tissue regeneration by repairing tissue via direct injection to a target region without surgical incision. In addition, the injectable composition may be used as a therapeutic agent for arthritis by alleviating osteoarthritis not only because the animal cartilage-derived extracellular matrix contained in the injectable composition protects articular cartilage tissue but also because an environment capable of regenerating damaged articular tissue is created by inducing differentiation of intra-articular stem cells into chondrocytes.

Abstract: Disclosed is the use of a cell-free fat extract for preparing a composition or a preparation. The composition or the preparation is used for preventing and/or treating ovarian insufficiency and/or complications thereof. The cell-free fat extract has an excellent therapeutic effect on ovarian insufficiency and/or complications thereof.

Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

Abstract: Compositions for reducing the emission of methane by ruminant animals are disclosed. The compositions include avian antibodies against methanogens generally found in the rumen of the animals. Egg contents of eggs from female birds inoculated with immunogenic compositions containing one or more methanogens or antigens derived from methanogens are used. The antibodies in the egg contents may be used directly without further purification, may be partially purified or purified. The compositions may be administered in drinking water or in animal feed. Administering of the anti-methanogenic composition reduces the emission of methane and increases the efficiency of feed conversion.

Abstract: The disclosure concerns methods for the inhibiting and treating of immune inflammation such as neuroinflammation, depression, anxiety, cognitive decline, nerve degeneration or the effect of aging, neurological disease, cognitive function, mental disorder, depression, anxiety disorders, stress, respiratory inflammation, post-nasal drip, sinus infections, chronic cough, infections, bacterial infection, viral infection, fungal infection, comprising administering a composition comprising a combination of herbal ingredients.

Abstract: A method of regulating blood pressure in a subject is provided. The method comprises administering a preparation comprising ammonia oxidizing microorganisms to the subject. thereby regulating blood pressure in the subject. Related preparations, kits, and devices are also provided.

Abstract: Ammonia oxidizing microorganism preparations for delivery to the visual and auditory systems, kits including ammonia oxidizing preparations for delivery to the visual and auditory systems, and devices for administering ammonia oxidizing preparations to the visual and auditory systems are provided. Methods of introducing ammonia oxidizing microorganisms to the eye are provided. Methods of introducing ammonia oxidizing microorganisms to the ear are provided. Methods of treating disorders, including eye disorders, ear disorders, and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

Abstract: The present disclosure relates to a method for treating or preventing a viral and/or bacterial respiratory infection in a subject, the method comprising administering to the respiratory tract of the subject an effective amount of one or more bacteria from family Pasteurellaceae.

Abstract: Described herein are compositions and methods of treatment for acne and other skin disorders involving the use of probiotics. In certain aspects, microbes included in the probiotics have been engineered or selected for the treatment of specific skin disorders.

Abstract: Provided herein are compositions comprising bacterial strains capable of metabolizing L-tryptophan to produce indole-containing metabolites, nutritional supplements and food products containing such bacterial strains, and methods of production thereof.

Abstract: Synbiotic compositions including both a prebiotic component and a probiotic component are provided. The prebiotic component includes at least one punicalagin, and the probiotic component includes a rationally defined and assembled consortium of microbial strains. Delivery capsules for oral administration of the synbiotic compositions and methods of using the synbiotic compositions to treat disease are also provided.

Abstract: Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.

Abstract: The present invention addresses the problem of providing a composition for increasing muscle mass and suppressing a decrease in muscle mass, and composition for increasing muscle mass and suppressing muscle atrophy, the compositions can be taken orally continuously in a daily basis. As a result of intensive research, the inventors solved the problem by preparing a composition for increasing muscle mass and suppressing a decrease in muscle mass, which contains as an effective component at least one selected from the group consisting of spirulina, phycocyanin, a spirulina enzymatically degraded product, and a phycocyanin enzymatically degraded product.

Abstract: Provided herein are methods and compositions for the treatment or prevention of a skin disease (e.g., acne) in a subject by administering to the subject a composition comprising a strain of P. granulosum, a strain of P. avidum, and/or a strain of P. humerusii. Also provided herein are methods of determining whether a subject has a skin condition, the method comprising measuring the amount of P. granulosum on the skin of the subject.

Abstract: The present invention discloses a recombinant bacteriophage comprising a phage genome polynucleotide including a gene encoding a heterologous antigen protein(s) and a killing gene encoding a protein that is capable of killing a host bacterium. Such a recombinant bacteriophage is designed to prime a subject's immune response and to kill the bacterium that it infects such that the “prime and kill” bacteriophage provides two lines of protection against infectious disease.

Abstract: Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.

Abstract: The present invention relates to a birnavirus for use in the treatment or prevention of cancer. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment or prevention of cancer. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment or prevention of cancer.

Abstract: Disclosed are methods for treating hematologic and solid cancers in a subject, the method comprising administering locally or systemically a therapeutically effective amount of a HRVA2.s and/or HRVA45.s alone or in combination with FDA approved or experimental immunomodulatory agents such that some cells of the cancer undergo viral oncolysis, wherein the host immune system is engaged culminating in host immune activation and tumor regression in the human or animal host. Disclosed are methods for treating viral induced lesions of the skin, including HPV driven papillomas in a subject, the method comprising administering a therapeutically effective amount of HRVA2.s and/or HRVA45.s alone or in combination with immunomodulatory agents such that some cells of the papilloma cells undergo selective viral lysis, wherein the host immune system is engaged culminating in host immune activation and papilloma in the subject.

Abstract: In aspects, a cannabis extract enriched in polyphenolic compounds is provided herein. Also provided herein is a method for enriching a composition with polyphenolic compounds as well as compositions made by the method. Various cosmetic and pharmaceutical products, methods, and uses are provided herein as well as natural health products.

Abstract: A Nepeta cataria L. extract including one of a compound of formula I and a compound of formula II, or a combination thereof is provided. Methods for shortening sleep latency, improving sleep quality, enhancing vitality of daytime activities, resisting depression, or protecting brain by using the Nepeta cataria L. extract are provided. The Nepeta cataria L. extract is obtained by extracting flower spikes of Nepeta cataria L. with water at 85° C.±5° C.

Abstract: Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.

Abstract: In an embodiment, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided. According to an embodiment of the present invention, a preparation for treatment of a novel coronavirus infection comprises Cepharanthine, Isotetrandrine, Cycleanine, and Berbamine. A preparation for treatment of a novel coronavirus infection is for treatment of an infection caused by the novel coronavirus mutant strain. According to an embodiment of the present invention, a Stephania cepharantha-derived alkaloid-containing preparation for treatment of a novel coronavirus infection is provided.

Abstract: The invention discloses a composition comprising Cyperus rotundus extract and Passiflora edulis extract comprising piceatannol, scirpusin B, scirpusin A, cyperusphenol A and cyperusphenol B, standardized to contain 6-10% w/w total stilbenes and a process of preparing the composition thereof. The invention also discloses the use of the above mentioned composition in enhancing energy expenditure in mammalian adipose cellular systems by the conversion of white adipose tissues to brown adipose tissues, inhibition of adipogenesis and for preventing weight gain in mammals.

Abstract: The present disclosure relates to methods and compositions that inhibit a tumor microenvironment and methods of co-administering such compositions to inhibit the tumor microenvironment and treat cancer in a subject.

Abstract: Disclosed herein are compositions and methods for promoting weight loss and/or preventing or obesity; improving athletic performance/endurance; improving muscle function; improving cognitive function; promoting weight management; improving cardiovascular health; improving blood flow; reducing inflammation; and/or immune modulation. In certain aspects, the disclosed method comprises administering a composition to a subject comprising combinations of dileucine and paraxanthine and/or dileucine and L-arginine and/or dileucine and leucine.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: The present disclosure provides methods for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with the subcutaneous administration of elamipretide, or a pharmaceutically acceptable salt thereof. The methods may involve administration of inhibitors of the MRGPRX2 receptor and/or inhibitors of mast cell degranulation. In some cases, the methods involve administration of an effective amount of a flavonoid, a coumarin, a phenol, or a terpenoid. Such methods may include applying mometasone furoate, tacrolimus, quercetin, diphenhydramine and/or ice to the elamipretide injection site or intended (injection site to treat, prevent, ameliorate, inhibit or delay the onset of said injection site reactions (ISRs). The present disclosure also provides methods for subcutaneously administering a 60 mg dose of elamipretide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

Abstract: The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

Abstract: Provided herein are methods and compositions for improving visual function in an eye of an individual having an ocular disorder. The methods described herein generally comprise methods of improving visual function (e.g., BCVA) in an eye of an individual having an ocular disease or disorder, comprising: administering a peptide (e.g., a composition comprising the peptide) comprising an amino acid sequence HHIYLGAVNYIY or a variant sequence thereof, or a pharmaceutically-acceptable salt of the peptide, to the eye of the individual.

Abstract: The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.

Abstract: The invention pertains to a liquid nutritional composition for use in prevention and/or treatment of whole body protein metabolism decline or whole body protein function decline, or for improving whole body protein metabolism or whole body protein function, particularly for use in muscle decline, or for improving muscle function, in a human subject suffering from metabolic stress and/or starvation, wherein the human subject is preferably a human elderly subject of at least 50 years of age, wherein the composition comprises a protein fraction comprising (a) 15 to 35 weight % of casein; (b) 25 to 50 weight % of whey protein; (c) 10 to 30 weight % of soy protein; and (d) 10 to 30 weight % of pea protein; relative to the total protein in the protein fraction, wherein the sum of said proteins preferably equals 100 weight % of the protein fraction.

Abstract: Knee pain caused by osteoarthritis is relieved by modifying the shape change of bone(s) underlying articular cartilage, by a method comprising evaluating the bone shape of the patient's joint, injecting the patient with a peptide of SEQ ID No. 1 or applying other therapeutic interventions that can reduce the shape change of the bone(s) underlying articular cartilage, and thereafter evaluating the bone shape of the patient's joint.

Abstract: The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII antagonists to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: A method to inhibit neutrophil recruitment to damaged tissue, thereby inhibiting inflammation in a subject. The method includes administering to an anti-inflammatory amount of a myeloid-derived growth factor (“MYDGF”). Also disclosed are corresponding pharmaceutical compositions of matter containing the MYDGF.

Abstract: A stabilized aPGF composition or a method for stabilization of the pharmaceutical composition comprising aFGF are provided. The composition comprises aPGF, a citric acid compound and other excipients. The method for improving stability of aPGF in the form of a liquid formulation or a lyophilized formulation so as to increase storage stability is also provided.

Abstract: The present inventors have discovered that a peptide derived from HMGB1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB1 which is different from conventional uses.

Abstract: Described herein are pharmaceutical compositions, medicaments and methods for providing effective immunomodulation with chimeric proteins including FasL moieties for selective and long-lasting regulation of the immune response.

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: Stable pharmaceutical formulations for therapeutic dual GLP-1 receptor/glucagon receptor agonists and methods of using such stable pharmaceutical formulations.

Abstract: The present invention relates to a combination therapy using an insulinotropic peptide and GLP-2 for the prevention, improvement, or treatment of short bowel syndrome.

Abstract: A composition an aqueous gel made up of therapeutically effective amounts of a hormone supplement, ?-Caryophyllene, cannabidiol, eucalyptol, menthol, one or more salicylic glycosides, and 2,5-Dimethoxy-p-cymene. The hormone supplement is made up of either homeopathic somatropin or L-DOPA, or both.

Abstract: A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4/CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

Abstract: A method of treating Alzheimer's disease (AD) in a subject includes administering to the subject a therapeutically effective amount of at least one parathyroid hormone type 1 receptor (PTH1R) agonist.

Abstract: Provided is a composition for improving, preventing, or treating inflammatory bowel disease including a NAMPT-derived peptide as an active ingredient. The NAMPT-derived peptide of the present disclosure may bind to TRL4 and/or CYBB competitively with extracellular NAMPT (eNAMPT) to inhibit NLRP3 inflammasome activation by the interaction of eNAMPT with TRL4 and/or CYBB, and the NAMPT-derived peptide of the present disclosure further includes a peptide targeting colon tissue to act directly on the colon, so that it is expected to be useful for the prevention or treatment of inflammatory bowel disease.

Abstract: Methods and compositions for the treatment of wounds and ulcers in patients, in particular those patients suffering from chronic, non-healing wounds and ulcers. Fibrinogenases, such as plasmin show utility in decreasing plasma and or blood viscosity resulting in improved wound and ulcer healing in patients. The fibrinogenase may be one selected from the group consisting of an ?-fibrinogenase, a ?-fibrinogenase, a ?-fibrinogenase, a metallo-?-fibrinogenase, allium-?-fibrinogenase, a plasmin, and combination thereof.

Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof and the use of proteolytic cleavage enzymes.